SK-1404
Phase 2Small molecule
SK-1404 is one of 12 small molecule programs targeting Polyuria. It is currently in Phase 2.
1
Indications
1
Total Trials
0
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
12 competitors in Polyuria
#DrugCompanyPhaseTrials
1Myrbetriq
AstellasApproved
Vesicare
AstellasApproved
Toviaz
PfizerApproved
Enablex
AbbVieApproved
Oxytrol
WWim Janssens
Approved
Pitressin
AAultman Health Foundation
Approved
Detrol La
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Desmopressin Melt
FerringPhase 3
FE 999301
FerringPhase 2
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SK-1404. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- SSanwa Kagaku Kenkyusho Co., Ltd.